Particle size-dependent triggering of accelerated blood clearance phenomenon

Hiroyuki Koide, Tomohiro Asai, Kentaro Hatanaka, Takeo Urakami, Takayuki Ishii, Eriya Kenjo, Masamichi Nishihara, Masayuki Yokoyama, Tatsuhiro Ishida, Hiroshi Kiwada, Naoto Oku

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

A repeat-injection of polyethylene glycol-modified liposomes (PEGylated liposomes) causes a rapid clearance of them from the blood circulation in certain cases that is referred to as the accelerated blood clearance (ABC) phenomenon. In the present study, we examined whether polymeric micelles trigger ABC phenomenon or not. As a preconditioning treatment, polymeric micelles (9.7, 31.5, or 50.2 nm in diameter) or PEGylated liposomes (119, 261 or 795 nm) were preadministered into BALB/c mice. Three days after the preadministration [3H]-labeled PEGylated liposomes (127 nm) as a test dose were administered into the mice to determine the biodistribution of PEGylated liposomes. At 24 h after the test dose was given, accelerated clearance of PEGylated liposomes from the bloodstream and significant accumulation in the liver was observed in the mice preadministered with 50.2-795 nm nanoassemblies (PEGylated liposomes or polymeric micelles). In contrast, such phenomenon was not observed with 9.7-31.5 nm polymeric micelles. The enhanced blood clearance and hepatic uptake of the test dose (ABC phenomenon) were related to the size of triggering nanoassemblies. Our study provides important information for developing both drug and gene delivery systems by means of nanocarriers.

Original languageEnglish
Pages (from-to)197-200
Number of pages4
JournalInternational Journal of Pharmaceutics
Volume362
Issue number1-2
DOIs
Publication statusPublished - Oct 1 2008
Externally publishedYes

Fingerprint

Particle Size
Liposomes
Micelles
Gene Transfer Techniques
Blood Circulation
Liver
Drug Delivery Systems
Injections

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Koide, H., Asai, T., Hatanaka, K., Urakami, T., Ishii, T., Kenjo, E., ... Oku, N. (2008). Particle size-dependent triggering of accelerated blood clearance phenomenon. International Journal of Pharmaceutics, 362(1-2), 197-200. https://doi.org/10.1016/j.ijpharm.2008.06.004

Particle size-dependent triggering of accelerated blood clearance phenomenon. / Koide, Hiroyuki; Asai, Tomohiro; Hatanaka, Kentaro; Urakami, Takeo; Ishii, Takayuki; Kenjo, Eriya; Nishihara, Masamichi; Yokoyama, Masayuki; Ishida, Tatsuhiro; Kiwada, Hiroshi; Oku, Naoto.

In: International Journal of Pharmaceutics, Vol. 362, No. 1-2, 01.10.2008, p. 197-200.

Research output: Contribution to journalArticle

Koide, H, Asai, T, Hatanaka, K, Urakami, T, Ishii, T, Kenjo, E, Nishihara, M, Yokoyama, M, Ishida, T, Kiwada, H & Oku, N 2008, 'Particle size-dependent triggering of accelerated blood clearance phenomenon', International Journal of Pharmaceutics, vol. 362, no. 1-2, pp. 197-200. https://doi.org/10.1016/j.ijpharm.2008.06.004
Koide, Hiroyuki ; Asai, Tomohiro ; Hatanaka, Kentaro ; Urakami, Takeo ; Ishii, Takayuki ; Kenjo, Eriya ; Nishihara, Masamichi ; Yokoyama, Masayuki ; Ishida, Tatsuhiro ; Kiwada, Hiroshi ; Oku, Naoto. / Particle size-dependent triggering of accelerated blood clearance phenomenon. In: International Journal of Pharmaceutics. 2008 ; Vol. 362, No. 1-2. pp. 197-200.
@article{320cc0dda424482c9b727279fe5817bc,
title = "Particle size-dependent triggering of accelerated blood clearance phenomenon",
abstract = "A repeat-injection of polyethylene glycol-modified liposomes (PEGylated liposomes) causes a rapid clearance of them from the blood circulation in certain cases that is referred to as the accelerated blood clearance (ABC) phenomenon. In the present study, we examined whether polymeric micelles trigger ABC phenomenon or not. As a preconditioning treatment, polymeric micelles (9.7, 31.5, or 50.2 nm in diameter) or PEGylated liposomes (119, 261 or 795 nm) were preadministered into BALB/c mice. Three days after the preadministration [3H]-labeled PEGylated liposomes (127 nm) as a test dose were administered into the mice to determine the biodistribution of PEGylated liposomes. At 24 h after the test dose was given, accelerated clearance of PEGylated liposomes from the bloodstream and significant accumulation in the liver was observed in the mice preadministered with 50.2-795 nm nanoassemblies (PEGylated liposomes or polymeric micelles). In contrast, such phenomenon was not observed with 9.7-31.5 nm polymeric micelles. The enhanced blood clearance and hepatic uptake of the test dose (ABC phenomenon) were related to the size of triggering nanoassemblies. Our study provides important information for developing both drug and gene delivery systems by means of nanocarriers.",
author = "Hiroyuki Koide and Tomohiro Asai and Kentaro Hatanaka and Takeo Urakami and Takayuki Ishii and Eriya Kenjo and Masamichi Nishihara and Masayuki Yokoyama and Tatsuhiro Ishida and Hiroshi Kiwada and Naoto Oku",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.ijpharm.2008.06.004",
language = "English",
volume = "362",
pages = "197--200",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Particle size-dependent triggering of accelerated blood clearance phenomenon

AU - Koide, Hiroyuki

AU - Asai, Tomohiro

AU - Hatanaka, Kentaro

AU - Urakami, Takeo

AU - Ishii, Takayuki

AU - Kenjo, Eriya

AU - Nishihara, Masamichi

AU - Yokoyama, Masayuki

AU - Ishida, Tatsuhiro

AU - Kiwada, Hiroshi

AU - Oku, Naoto

PY - 2008/10/1

Y1 - 2008/10/1

N2 - A repeat-injection of polyethylene glycol-modified liposomes (PEGylated liposomes) causes a rapid clearance of them from the blood circulation in certain cases that is referred to as the accelerated blood clearance (ABC) phenomenon. In the present study, we examined whether polymeric micelles trigger ABC phenomenon or not. As a preconditioning treatment, polymeric micelles (9.7, 31.5, or 50.2 nm in diameter) or PEGylated liposomes (119, 261 or 795 nm) were preadministered into BALB/c mice. Three days after the preadministration [3H]-labeled PEGylated liposomes (127 nm) as a test dose were administered into the mice to determine the biodistribution of PEGylated liposomes. At 24 h after the test dose was given, accelerated clearance of PEGylated liposomes from the bloodstream and significant accumulation in the liver was observed in the mice preadministered with 50.2-795 nm nanoassemblies (PEGylated liposomes or polymeric micelles). In contrast, such phenomenon was not observed with 9.7-31.5 nm polymeric micelles. The enhanced blood clearance and hepatic uptake of the test dose (ABC phenomenon) were related to the size of triggering nanoassemblies. Our study provides important information for developing both drug and gene delivery systems by means of nanocarriers.

AB - A repeat-injection of polyethylene glycol-modified liposomes (PEGylated liposomes) causes a rapid clearance of them from the blood circulation in certain cases that is referred to as the accelerated blood clearance (ABC) phenomenon. In the present study, we examined whether polymeric micelles trigger ABC phenomenon or not. As a preconditioning treatment, polymeric micelles (9.7, 31.5, or 50.2 nm in diameter) or PEGylated liposomes (119, 261 or 795 nm) were preadministered into BALB/c mice. Three days after the preadministration [3H]-labeled PEGylated liposomes (127 nm) as a test dose were administered into the mice to determine the biodistribution of PEGylated liposomes. At 24 h after the test dose was given, accelerated clearance of PEGylated liposomes from the bloodstream and significant accumulation in the liver was observed in the mice preadministered with 50.2-795 nm nanoassemblies (PEGylated liposomes or polymeric micelles). In contrast, such phenomenon was not observed with 9.7-31.5 nm polymeric micelles. The enhanced blood clearance and hepatic uptake of the test dose (ABC phenomenon) were related to the size of triggering nanoassemblies. Our study provides important information for developing both drug and gene delivery systems by means of nanocarriers.

UR - http://www.scopus.com/inward/record.url?scp=50249101054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249101054&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2008.06.004

DO - 10.1016/j.ijpharm.2008.06.004

M3 - Article

C2 - 18586076

AN - SCOPUS:50249101054

VL - 362

SP - 197

EP - 200

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -